Hemochromatosis Clinical Trials

Find Hemochromatosis Clinical Trials Near You

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects With HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)

Status: Active_not_recruiting
Location: See all (97) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study to assess vamifeport in adult participants with homeostatic iron regulator gene-related hereditary hemochromatosis (HFE-HH). The primary objective of the study is to assess the effect of vamifeport treatment on magnetic resonance imaging (MRI)-based liver iron concentration (LIC) in adult participants with HFE-HH.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult (≥ 18 years) and has provided written informed consent.

• Confirmed diagnosis of HFE-HH in medical history.

• Evidence of iron overload as shown by:

‣ TSAT \> 45% (confirmed at 2 visits, at least 14 days apart) at Screening; and

⁃ Serum ferritin ≥ 200 nanogram per milliliter (ng/mL) and \< 5000 ng/mL (confirmed at 2 visits, at least 14 days apart) at Screening; and

⁃ MRI-based LIC between 2.4 and 16 mg/g (43.0 and 286.5 mmol/kg) dry weight (dw) at Screening.

• Body mass index between 18.5 and 34.9 kilograms per meter squared (kg/m\^2).

Locations
United States
Arizona
Banner MD Anderson
Gilbert
California
Infinity Clinical Trials
San Diego
Medical Oncology Associates of San Diego
San Diego
Florida
Green Leaf Clinical Trials
Jacksonville
Global Medical Research Management LLC
Miami
Indiana
Indiana University Health University Hospital
Indianapolis
Louisiana
Ochsner Medical Complex - High Grove
Baton Rouge
Maryland
Johns Hopkins University School of Medicine
Baltimore
American Oncology Partners, PA dba The Center for Cancer and Blood Disorders
Bethesda
James M. Stockman Cancer Institute
Frederick
Michigan
University of Michigan Health System (UMHS)
Ann Arbor
Minnesota
Aspirus St. Luke's Clinic - Duluth - Oncology & Hematology
Duluth
North Carolina
University of North Carolina at Chapel Hill
Chapel Hill
Duke University Medical Center (Duke South Clinics) -40 Duke Medicine Cir
Durham
New Jersey
Hunterdon Hematology Oncology, LLC
Flemington
Oklahoma
Hightower Clinical - Oklahoma Cancer Center
Oklahoma City
Pennsylvania
Cancer Care Associates of York
York
Utah
Intermountain Medical Center
Murray
Washington
Velocity Clinical Research - Seattle
Seattle
Washington State Univ Elson S. Floyd College of Medicine
Spokane
Other Locations
Australia
Royal Brisbane and Women's Hospital
Brisbane
Gallipoli Medical Research
Chandler
Monash Medical Centre
Clayton
Trials West
Perth
Westmead Hospital for Medical Research
Westmead
Austria
Medical University of Innsbruck
Innsbruck
Ordensklinikum Linz - Barmherzige Schwestern
Linz
Medical University Vienna
Vienna
Belgium
Universitair Ziekenhuis Antwerpen (UZA)
Edegem
Ghent University Hospital
Ghent
UZ Brussel
Jette
Centre Hospitalier Universitaire de Liège (CHU de Liège)
Liège
CHU UCL Namur - Site Godinne
Yvoir
Canada
Libin Cardiovascular Institute University of Calgary
Calgary
McMaster University-St. Josephs Healthcare Hamilton
Hamilton
University of Manitoba
Winnipeg
Denmark
Aarhus University Hospital
Aarhus
Bispebjerg Hospital
Copenhagen
Copenhagen University Hospital - Hvidovre
Hvidovre
France
Aphp Avicenne
Bobigny
Chu Dupuytren
Limoges
CRMR Maladies du Globule Rouge, Hôpital de la Timone
Marseille
CHU de Montpellier- Hôpital Saint Eloi
Montpellier
GHRMSA
Mulhouse
CHU de Bordeaux - Hôpital Haut Leveque
Pessac
Centre Hospitalier Lyon Sud/Hospices Civils de Lyon
Pierre-bénite
Chu Rennes
Rennes
Centre Hospitalier de Saint Brieuc
Saint-brieuc
CHU Toulouse
Toulouse
Hôpital Paul Brousse
Villejuif
Germany
Universitätsklinikum Freiburg
Freiburg Im Breisgau
University Hospital Heidelberg
Heidelberg
EUGASTRO GmbH
Leipzig
MVZ für Innere Medizin Weinheim
Weinheim
Ireland
Cork University Hospital
Cork
Beaumont Hospital
Dublin
Connolly Hospital Blanchardstown
Dublin
Italy
ASL Brindisi - Presidio Ospedaliero Di Summa - Perrino
Brindisi
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Milan
University Hospital of Modena
Modena
Fondazione IRCCS San Gerardo dei Tintori
Monza
AORN Cardarelli
Naples
University of Verona - Azienda Ospedaliera Universitaria Integrata Verona
Verona
Netherlands
Maastricht UMC
Maastricht
Radboud UMC
Nijmegen
New Zealand
Aotearoa Clinical Trials Trust- Middlemore Hospital
Auckland
Auckland City Hospital
Auckland
Poland
Specjalistyczny Szpital im. Alfreda Sokolowskiego
Wałbrzych
Instytut Hematologii i Transfuzjologii
Warsaw
Wojewodzki Szpital im. J Gromkowskiego we Wroclawiu
Wroclaw
Romania
Spitalul Clinic de Urgenta Prof Dr Agrippa Ionescu-Balotesti
Baloteşti
Bistrița County Emergency Clinical Hospital
Bistriţa
Coltea Clinical Hospital
Bucharest
L'Institute Oncologique Prof. Dr. Ion Chiricuta (IOCN)
Cluj-napoca
Prof. Dr.Octavian Fodor Regional Institute of Gastroenterology-Hepatology
Cluj-napoca
Spain
Hospital Universitari Germans Trias i Pujol
Badalona
Hospital Clinic Barcelona
Barcelona
HUGC Doctor Negrin
Las Palmas De Gc
Hospital Universitario La Paz
Madrid
Hospital Universitario Puerta de Hierro - Majadahonda
Majadahonda
Althaia Foundation. Hospital Sant Joan de Deu de Manresa
Manresa
Hospital Universitario Virgen del Rocío
Seville
Switzerland
University Hospital Inselspital Bern
Bern
Centre Hospitalier Universitaire Vaudois
Lausanne
Epatocentro Ticino
Lugano
United Kingdom
Royal Victoria Hospital
Belfast
University Hospitals Bristol and Weston NHS trust, Bristol Haematology and Oncology Centre
Bristol
University Hospital Hairmyres-PPDS
Glasgow
Royal Liverpool University Hospital
Liverpool
King's College Hospital
London
St Thomas Hospital
London
Norfolk and Norwich University Hospital
Norwich
Nottingham University Hospitals City Campus
Nottingham
John Radcliffe Hospital - Oxford University Hospitals NHS
Oxford
Derriford Hospital
Plymouth
University Hospital Southampton NHS Foundation Trust
Southampton
South Warwickshire University Foundation Trust
Warwick
Time Frame
Start Date: 2026-01-22
Completion Date: 2028-05-15
Participants
Target number of participants: 84
Treatments
Experimental: Vamifeport Low Dose
Participants will receive a low dose of vamifeport orally, twice daily (BID) up to Day 360.
Experimental: Vamifeport High Dose
Participants will receive a high dose of vamifeport orally, BID up to Day 360.
Placebo_comparator: Placebo
Participants will receive placebo matching vamifeport low and high doses orally, BID up to Day 360.
Related Therapeutic Areas
Sponsors
Leads: CSL Behring

This content was sourced from clinicaltrials.gov